Results of Annual General Meeting

Genflow Biosciences PLC

08 June 2023

 

8 June 2023

Genflow Biosciences Plc

("Genflow" or "the Company")

Results of Annual General Meeting

Genflow (LSE: GENF), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age, is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed.

For further information please contact:

Genflow Biosciences Plc
Dr Eric Leire Chief Executive	[phone]
Clear Capital Markets Ltd
Corporate Broker  Andrew Blaylock	[phone]

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.

Its mission is to increase our understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit www.genflowbio.com

-Ends-

 

END